On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
TARRYTOWN, N.Y. and PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the presentation of positive results from the pivotal ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
Since its initial approval for moderate-to-severe atopic dermatitis, Dupixent has secured approvals across eight other diseases, including severe chronic rhinosinusitis with nasal polyposis, severe ...
Regeneron REGN along with partner Sanofi SNY announced positive data from the pivotal phase III BOREAS study on their blockbuster drug, Dupixent (dupilumab), for treating chronic obstructive pulmonary ...
Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results